 "Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore")
Mumbai-headquartered Glenmark Pharmaceuticals posted a 31 per cent decline in net profit for the first quarter of the financial year to Rs 211.1 crore, as the consolidated revenues dipped from Rs 2,965 crore in the previous corresponding quarter to Rs 2,777.3 crore in Q1FY23. The results were declared after market hours.
The revenues dipped by 6.3 per cent year-on-year (YoY), but the company said that when viewed without taking into account the global sales of Covid-related products in the first quarter of FY 2021-22, the base business showed a YoY growth of 10.4 per cent in the current fiscal.
Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent. “Reported Ebidta was Rs 431.6 crore in the quarter ended June 30, 2022, with margins of 15.5 per cent,” the company said in a statement.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →Subscribe to Business Standard digital and get complimentary access to The New York Times
Quarterly Starter
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
Save 46%
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%